Sagimet Biosciences Inc.
SGMT
$7.11
-$0.24-3.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.86% | -12.19% | -10.82% | -80.08% | -22.46% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.47% | -35.58% | 43.47% | 4.87% | 67.28% |
| Change in Net Operating Assets | -104.69% | -27.25% | 160.97% | -506.64% | 916.02% |
| Cash from Operations | 37.39% | -31.86% | 43.67% | -247.34% | 9.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -489.39% | -65.35% | 1,478.53% | 100.83% | -2,605.23% |
| Cash from Investing | -489.39% | -65.35% | 1,478.53% | 100.83% | -2,605.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 97.35% |
| Cash from Financing | -- | -- | -- | 100.00% | -100.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -101.29% | -847.44% | 93.80% | 76.56% | -179.52% |